Background
Tumors
BONE LESIONS, CASTRATION-RESISTANT PROSTATE CANCER, TUMORS, SCLEROTIC, BONE METASTASES
Radium-223 is a bone-seeking, ɑ-emitting radionuclide used to treat men with bone metastases from castration-resistant prostate cancer. Sclerotic bone lesions cannot be evaluated using Response Evaluation Criteria in Solid Tumors. Therefore, imaging response biomarkers are needed.